We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
GEHC Stock Gains Post Latest Launch to Optimize Radiology Workflows
Read MoreHide Full Article
Key Takeaways
GE HealthCare launched Genesis Radiology Workspace to improve radiology workflow and efficiency.
GEHC's solution combines AI, cloud access and fast diagnostics to cut turnaround times and boost accuracy.
GE HealthCare expects this launch to strengthen its Enterprise Imaging unit and radiology market presence.
Yesterday, GE HealthCare Technologies Inc. (GEHC - Free Report) unveiled the Genesis Radiology Workspace. It is a next-generation solution built to transform radiology workflows, deliver a unified user experience and enable radiologists to work with greater efficiency and precision.
Per GEHC, Genesis View, whose 510(k) approval is pending, sits at the heart of this innovation. It is a powerful new viewer built as a fast diagnostic, zero-footprint solution that streamlines radiology workflows to enhance patient care, while remaining fully accessible from any location.
The latest offering is expected to significantly boost GE HealthCare’s Enterprise Imaging business and strengthen its foothold in the radiology space.
Trend in GEHC Stock Following the News
Following the announcement, shares of the company gained nearly 2.2% till yesterday’s close.
Historically, the company has gained a top-line boost from its various product innovations and launches. We expect market sentiment on the stock to remain positive around this announcement, too.
GE HealthCare currently has a market capitalization of $36.51 billion. It has an earnings yield of 5.7%. In the last reported quarter, GEHC delivered an earnings surprise of 1.9%.
Significance of GE HealthCare’s Latest Offering
Per GE HealthCare, medical imaging departments are currently facing intense pressure on multiple fronts, like rising imaging volumes and growing case complexity, while staffing shortages continue to worsen. This makes the ability to interpret studies from anywhere essential for maintaining throughput and ensuring timely diagnoses. However, studies show that radiologists spend up to 64% of their time on non-interpretive tasks, such as navigating complex interfaces or waiting for images to load, which directly impacts productivity and turnaround times.
Management believes that Genesis Radiology Workspace combines cloud-native accessibility with embedded AI and advanced visualization to enable diagnostic imaging professionals to work smart, fast and from anywhere without compromising diagnostic accuracy. The solution is expected to streamline workflows, reduce cognitive burden and improve patient care.
Industry Prospects in Favor of GEHC
Per a report by Data Bridge Market Research, the global radiology market was valued at $31.86 billion in 2024 and is anticipated to reach $51.55 billion by 2032 at a CAGR of 6.2%. Factors like technological advancements in imaging modalities, increasing demand for early and accurate diagnosis and the increasing adoption of advanced imaging technologies are likely to drive the market.
Given the market potential, the latest launch is expected to provide a significant boost to GE HealthCare’s business.
GE HealthCare’s Recent Developments
This month, GE HealthCare announced the submission of a 510(k) approval to the FDA seeking clearance for Photonova Spectra. It is the company’s new photon-counting computed tomography system with advanced AI algorithms.
The same month, GEHC entered into an agreement to acquire Intelerad, a renowned medical imaging software provider for the healthcare industry. This will likely create a fully-connected, cloud-first imaging ecosystem spanning high-growth outpatient and ambulatory, teleradiology and hospital settings.
GEHC’s Share Price Performance
Shares of the company have lost 3.6% in the past year compared with the industry’s 0.9% decline. The S&P 500 has gained 14.8% in the same time frame.
Image Source: Zacks Investment Research
GE HealthCare’s Zacks Rank & Key Picks
Currently, GEHC carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Boston Scientific Corporation (BSX - Free Report) , Cencora, Inc. (COR - Free Report) and IDEXX Laboratories, Inc. (IDXX - Free Report) .
Boston Scientific, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 16.4%. BSX’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 7.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Boston Scientific’s shares have gained 11.7% against the industry’s 0.9% decline in the past year.
Cencora, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 11.9%. COR’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 5.5%.
Cencora has rallied 50.1% compared with the industry’s 1.3% gain in the past year.
IDEXX, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 13%. IDXX’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 7.1%.
IDEXX’s shares have gained 81.8% compared with the industry’s 2.8% gain in the past year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
GEHC Stock Gains Post Latest Launch to Optimize Radiology Workflows
Key Takeaways
Yesterday, GE HealthCare Technologies Inc. (GEHC - Free Report) unveiled the Genesis Radiology Workspace. It is a next-generation solution built to transform radiology workflows, deliver a unified user experience and enable radiologists to work with greater efficiency and precision.
Per GEHC, Genesis View, whose 510(k) approval is pending, sits at the heart of this innovation. It is a powerful new viewer built as a fast diagnostic, zero-footprint solution that streamlines radiology workflows to enhance patient care, while remaining fully accessible from any location.
The latest offering is expected to significantly boost GE HealthCare’s Enterprise Imaging business and strengthen its foothold in the radiology space.
Trend in GEHC Stock Following the News
Following the announcement, shares of the company gained nearly 2.2% till yesterday’s close.
Historically, the company has gained a top-line boost from its various product innovations and launches. We expect market sentiment on the stock to remain positive around this announcement, too.
GE HealthCare currently has a market capitalization of $36.51 billion. It has an earnings yield of 5.7%. In the last reported quarter, GEHC delivered an earnings surprise of 1.9%.
Significance of GE HealthCare’s Latest Offering
Per GE HealthCare, medical imaging departments are currently facing intense pressure on multiple fronts, like rising imaging volumes and growing case complexity, while staffing shortages continue to worsen. This makes the ability to interpret studies from anywhere essential for maintaining throughput and ensuring timely diagnoses. However, studies show that radiologists spend up to 64% of their time on non-interpretive tasks, such as navigating complex interfaces or waiting for images to load, which directly impacts productivity and turnaround times.
Management believes that Genesis Radiology Workspace combines cloud-native accessibility with embedded AI and advanced visualization to enable diagnostic imaging professionals to work smart, fast and from anywhere without compromising diagnostic accuracy. The solution is expected to streamline workflows, reduce cognitive burden and improve patient care.
Industry Prospects in Favor of GEHC
Per a report by Data Bridge Market Research, the global radiology market was valued at $31.86 billion in 2024 and is anticipated to reach $51.55 billion by 2032 at a CAGR of 6.2%. Factors like technological advancements in imaging modalities, increasing demand for early and accurate diagnosis and the increasing adoption of advanced imaging technologies are likely to drive the market.
Given the market potential, the latest launch is expected to provide a significant boost to GE HealthCare’s business.
GE HealthCare’s Recent Developments
This month, GE HealthCare announced the submission of a 510(k) approval to the FDA seeking clearance for Photonova Spectra. It is the company’s new photon-counting computed tomography system with advanced AI algorithms.
The same month, GEHC entered into an agreement to acquire Intelerad, a renowned medical imaging software provider for the healthcare industry. This will likely create a fully-connected, cloud-first imaging ecosystem spanning high-growth outpatient and ambulatory, teleradiology and hospital settings.
GEHC’s Share Price Performance
Shares of the company have lost 3.6% in the past year compared with the industry’s 0.9% decline. The S&P 500 has gained 14.8% in the same time frame.
Image Source: Zacks Investment Research
GE HealthCare’s Zacks Rank & Key Picks
Currently, GEHC carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Boston Scientific Corporation (BSX - Free Report) , Cencora, Inc. (COR - Free Report) and IDEXX Laboratories, Inc. (IDXX - Free Report) .
Boston Scientific, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 16.4%. BSX’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 7.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Boston Scientific’s shares have gained 11.7% against the industry’s 0.9% decline in the past year.
Cencora, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 11.9%. COR’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 5.5%.
Cencora has rallied 50.1% compared with the industry’s 1.3% gain in the past year.
IDEXX, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 13%. IDXX’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 7.1%.
IDEXX’s shares have gained 81.8% compared with the industry’s 2.8% gain in the past year.